Testing HLX43 for advanced hormone-sensitive breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This study tests a new drug called HLX43 for people whose breast cancer has continued to grow after hormone therapy. The goal is to see if HLX43 can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have advanced or metastatic breast cancer that is hormone receptor positive and HER2 negative.
- Your cancer must have continued to grow after at least one previous hormonal therapy for advanced breast cancer.
- You must have a tumor that can be measured on a scan (not just in the bone).
- You should be healthy enough to do daily activities (ECOG performance status 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, HLX43, by itself or combined with other immunotherapy drugs for people with advanced triple-negative breast cancer (TNBC) that has spread or cannot be removed by surgery. The goal is to see if these treatments can shrink tumors or slow cancer growth.
This trial tests a new drug, HLX43, for people with advanced non-small cell lung cancer that has not responded to standard treatments. It aims to see if HLX43 can help shrink or control the cancer.
This trial tests a new drug called HLX43 for people with advanced or metastatic solid tumors that have not responded to standard treatments. It aims to find safe dosing and understand how the drug works in the body.
This trial tests a new drug, HLX43, that targets a protein called PD-L1 on cancer cells and delivers a chemotherapy-like payload directly to them. It's for people with advanced colorectal cancer that hasn't responded to standard treatments.
This trial tests a new drug, HLX43, for people with advanced liver cancer (HCC) that has worsened or caused intolerable side effects after standard treatments like immunotherapy or targeted therapy. The goal is to see if HLX43 can help when other options have stopped working.
This trial tests a new drug, HLX43, that targets a protein called PD-L1 found on some cancer cells. It is for people with advanced cervical or ovarian cancer that has stopped responding to standard treatments.
Hear when a new Hormone Receptor Positive HER-2 Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.